Bram Priem
Impact in
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
-
- Atherosclerosis and Cardiovascular Diseases
- Immunotherapy and Immune Responses
Papers in
-
- Immune responses and vaccinations 2
- Atherosclerosis and Cardiovascular Diseases 2
- Immunotherapy and Immune Responses 1
-
- Nanoparticle-Based Drug Delivery 2
- Co-authors
- Willem J. M. Mulder (6 shared papers)Róbert Langer (3 shared papers)YongTae Kim (3 shared papers)Zahi A. Fayad (3 shared papers)Jun Tang (3 shared papers)Mihai G. Netea (2 shared papers)Mandy M. T. van Leent (2 shared papers)David P. Schrijver (1 shared paper)
- Journals
- Bioconjugate Chemistry (2 papers)Nature Reviews Materials (1 paper)Cell Research (1 paper)Expert Opinion on Drug Delivery (1 paper)Nanoscale (1 paper)
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
Bram Priem
7 papers receiving 368 citations
Peers
Comparison fields: 5 of 66
- Biomaterials 136
- Immunology 93
- Pharmaceutical Science 25
- Biomedical Engineering 143
- Cancer Research 33
Countries citing papers authored by Bram Priem
This map shows the geographic impact of Bram Priem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bram Priem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bram Priem more than expected).
Fields of papers citing papers by Bram Priem
This network shows the impact of papers produced by Bram Priem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bram Priem. The network helps show where Bram Priem may publish in the future.
Co-authors
The 25 scholars most cited alongside Bram Priem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 137 | |
| 2 | 2013 | 103 | |
| 3 | 2022 | 89 | |
| 4 | 2015 | 25 | |
| 5 | 2014 | 12 | |
| 6 | 2025 | 6 | |
| 7 | 2021 | 5 | |
| 8 | HDL-Mimetic PLGA Nanoparticle To Target Atherosclerosis Plaque Macrophages | 2015 | 0 |
About Bram Priem
Bram Priem is a scholar working on Immunology, Biomaterials, Obstetrics and Gynecology, Biomedical Engineering and Infectious Diseases, having authored 8 papers that have together received 377 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (2 papers), Immune responses and vaccinations (2 papers), COVID-19 Impact on Reproduction (2 papers), Atherosclerosis and Cardiovascular Diseases (2 papers), Nanoplatforms for cancer theranostics (2 papers), Diabetes and associated disorders (1 paper), Immunotherapy and Immune Responses (1 paper) and Advanced Drug Delivery Systems (1 paper). The work is most often cited by research in Biomaterials (136 citations), Immunology (93 citations), Pharmaceutical Science (25 citations), Biomedical Engineering (143 citations) and Cancer Research (33 citations). Bram Priem has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Willem J. M. Mulder, Róbert Langer, YongTae Kim, Zahi A. Fayad, Jun Tang, Mihai G. Netea, Mandy M. T. van Leent, David P. Schrijver, Thijs J. Beldman and Anne de Dreu. Their work appears in journals such as Bioconjugate Chemistry, Nature Reviews Materials, Cell Research, Expert Opinion on Drug Delivery and Nanoscale.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.